APA (7th ed.) Citation

Johannes Griss, Gudrun Ratzinger, Julia‐Tatjana Maul, Wolfgang Weger, Diamant Thaçi, José Manuel Carrascosa, & Constanze Jonak. (2023). No impact of disease duration on response to tildrakizumab treatment among patients with moderate‐to‐severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies. Wiley.

Chicago Style (17th ed.) Citation

Johannes Griss, Gudrun Ratzinger, Julia‐Tatjana Maul, Wolfgang Weger, Diamant Thaçi, José Manuel Carrascosa, and Constanze Jonak. No Impact of Disease Duration on Response to Tildrakizumab Treatment Among Patients with Moderate‐to‐severe Plaque Psoriasis: Post Hoc Analyses from Two Phase 3 (reSURFACE 1 and ReSURFACE 2) and One Phase 4 (TRIBUTE) Studies. Wiley, 2023.

MLA (9th ed.) Citation

Johannes Griss, et al. No Impact of Disease Duration on Response to Tildrakizumab Treatment Among Patients with Moderate‐to‐severe Plaque Psoriasis: Post Hoc Analyses from Two Phase 3 (reSURFACE 1 and ReSURFACE 2) and One Phase 4 (TRIBUTE) Studies. Wiley, 2023.